Search Results  for '4107.TWO'

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Bioteque Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

06 Feb 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for Bioteque Corporation

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

09 Feb 2016 Wright Reports 56 $75.00

Thomson Reuters Stock Report - Bioteque Corp (4107-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

08 Feb 2016 Thomson Reuters Stock Report 11 $25.00

邦特(4107.TT) 菲律賓廠相關許可證將陸續取得,1Q16營收創高可期

營運逐季走高,維持買進:研調處拜訪邦特後,對公司投資評等維持買進,主因(1)短期而言,1Q在菲律賓廠相關許可證陸續取得下,營收將再走高;(2)新廠產能移轉,長期有助營收及毛利率穩健上揚,維持買進,目標價因獲利微幅調整,由163調整至160元( 25 ...

27 Jan 2016 SinoPac Sec Investment Service Traditional Chinese 4 $23.00

Bioteque Corporation (4107) - Financial Analysis Review

Bioteque Corporation (4107) - Financial Analysis Review Summary Bioteque Corporation (Bioteque) is a medical device com...

21 Jan 2016 GlobalData 22 $125.00

Will Bioteque Corporation Deliver Long-Term Returns?

11 Jan 2016 Sadif Analytics Prime 12 $25.00

Bioteque Corporation (4107) - Financial Analysis Review

Bioteque Corporation (4107) - Financial Analysis Review Summary Bioteque Corporation (Bioteque) is a medical device com...

18 Dec 2015 GlobalData 22 $125.00

邦特(4107.TT)4Q營收創新高且2016營運強勁成長趨勢明確 調升評等至買進

2016營運強勁成長趨勢明確,調升評等至買進:研調處拜訪邦特後,對公司投資評等調升至買進,主因(1)訂單能見度高且產品滲透率也持續提升下,4Q營收將創歷史新高;(2)產品組合優化加上菲律賓新廠放量生產,2015及2016年獲利分別成長19.5%及28...

10 Nov 2015 SinoPac Sec Investment Service Traditional Chinese 4 $23.00

Should Investors Steer Clear of the Bioteque Corporation?

05 Oct 2015 Sadif Analytics Prime 12 $25.00

邦特(4107.TT)2016營運大放異彩,調升至買進

2016營運將大放異彩,投資價值浮現,調升至買進:研調處拜訪邦特後,對公司投資評等調升至買進,主因(1)菲律賓新廠與台灣廠間血液迴路管產品轉移順利,待產品銷售許可證及自由銷售許可證拿取後,4Q營收表現可期;(2)產品優化及經濟規模效應,毛利率還有再提...

19 Aug 2015 SinoPac Sec Investment Service Traditional Chinese 5 $35.00